A Rapid Image Analysis Method to Diagnose Alzheimer's Disease

VTT Technical Research Centre of Finland has developed a method for analysing MR images in just a few minutes when diagnosing Alzheimer's disease. The accuracy of the analysis is comparable to manual measurements made by skilled professionals, which are currently considered the most reliable method for diagnosing Alzheimer's disease. The accurate and rapid analysis method is well suited for clinical use.

Early detection of Alzheimer's disease requires that the patient displays some other symptom or sign of Alzheimer's disease in addition to memory problems. Such other symptoms include atrophy, i.e. the loss of brain cells, visible in MR images. One of the first areas of the brain where atrophy can be detected is the hippocampus. With VTT's new method, the volume of the hippocampus can be accurately calculated automatically.

Currently, diagnosis of Alzheimer's disease often makes use of visual assessment of MR images. Manual determination of brain structures in this way is a difficult task for the physician, and the repeatability of results typically poor. This has led to a high demand for objective methods. Earlier automatic systems for calculating the volume of the hippocampus are not in general clinical use because of deficiencies in speed and reliability.

Using VTT's new method, the assessment of MR images takes 3 minutes. With the fastest currently available automatic MR image assessment methods, the assessment takes 15 to 20 minutes. However, it is not uncommon for assessments to last for several hours.

The new method is part of a system which is currently being developed under the EU PredictAD project to help diagnose Alzheimer's disease. The system will be completed in 2011. The aim of the project is to develop objective methods which are sufficiently accurate, reliable and fast for clinical use but do not require large investments in equipment.

Other organisations involved in developing the new method include GE Healthcare (Uppsala, Sweden), Imperial College London (UK), University of Eastern Finland (Kuopio, Finland) and Rigshospitalet (Copenhagen, Denmark). The method is currently being tested to guarantee its operational reliability.

Results on the functionality of the new system have been published in NeuroImage.

About VTT Technical Research Centre of Finland
VTT Technical Research Centre of Finland is the biggest contract research organization in Northern Europe. VTT provides high-end technology solutions and innovation services. From its wide knowledge base, VTT can combine different technologies, create new innovations and a substantial range of world-class technologies and applied research services, thus improving its clients' competitiveness and competence. Through its international scientific and technology network, VTT can produce information, upgrade technology knowledge and create business intelligence and value added to its stakeholders. For more information, visit http://www.vtt.fi.

Most Popular Now

Significant Disparities in Telemedicine …

After "COVID-19," the term that most people will remember best from 2020 is likely to be "social distancing." While it most commonly applied to social gatherings with family and friends...

Model Used to Evaluate Lockdowns was Fla…

In a recent study, researchers from Imperial College London developed a model to assess the effect of different measures used to curb the spread of the coronavirus. However, the model...

Using Artificial Intelligence to Find Ne…

Scientists have developed a machine-learning method that crunches massive amounts of data to help determine which existing medications could improve outcomes in diseases for which they are not prescribed. The intent...

FDA Releases Artificial Intelligence / M…

Today, the U.S. Food and Drug Administration released the agency's first Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD) Action Plan. This action plan describes a multi-pronged approach...

New Virtual Screening Strategy Identifie…

A novel computational drug screening strategy combined with lab experiments suggest that pralatrexate, a chemotherapy medication originally developed to treat lymphoma, could potentially be repurposed to treat COVID-19. Haiping Zhang...

CliniSys Launches Laboratory Information…

CliniSys has launched a new laboratory information management system for genomic laboratories in the UK. The company has brought GLIMS Genomics to the UK from Europe, where it is being...

The Institute of Healthcare Management C…

The Institute of Healthcare Management has called for honest and open communication about NHS capacity after a snapshot survey revealed the scale of sickness absence across the service. The UK's leading...

One in Four Doctors Attacked, Harassed o…

While many physicians benefit from social media by networking with potential collaborators or interfacing with patients, a new study from Northwestern University and the University of Chicago found many physicians...

First NHS Trust and Sectra Achieve Rapid…

A new region-wide approach to analysing x-rays, MRI scans, CT scans, mammography, and an entire range of crucial diagnostic images, has started to become reality, now that The Pennine Acute...

Abbott to Launch the NeuroSphere™ myPath…

Abbott (NYSE: ABT) today announced the upcoming launch of NeuroSphere™ myPath™, a digital health app designed to track and report on patient perceived pain relief and general well-being associated with...

Bayer Transforms Pharma Business through…

At its virtual Pharma Media Day, Bayer presented exciting progress in transforming its pharmaceutical business with breakthrough innovation in healthcare that will significantly help patients suffering from conditions that are...